Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.86 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.86 |
| ▸ | KDM1A | O60341 | 2/20 | 0.82 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.80 |
| ▸ | GSK3B | P49841 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.71 |
| ▸ | UBE2N | P61088 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.66 |
| ▸ | P4HB | P07237 | 1/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696687 | 1.00 | PTPN1 (0.86) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL318230 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL318229 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL29336352 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL31233342 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL1122487 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL31233345 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL2532187 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL13625098 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B | |
| Prunin SCHEMBL29560212 | 0.93 | SLCO2B1 (1.00) | PTPN1SLCO2B1KDM1ASYNJ2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| CN-119112963-A | Compound Chinese medicinal powder and its preparation method | 右江民族医学院 | 2024-12-13 | — | — | CN | disclosed |
| CN-118903290-A | Traditional Chinese medicine composition and preparation method thereof | 广西医科大学 | 2024-11-08 | — | — | CN | disclosed |
| EP-4147054-A1 | HISTOCHEMICAL SYSTEMS AND METHODS FOR EVALUATING EGFR AND EGFR LIGAND EXPRESSION IN TUMOR SAMPLES | Ventana Medical Systems, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| CN-114514235-A | Novel galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114450282-A | Novel galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3990649-A1 | RANDOMIZED CONFIGURATION TARGETED INTEGRATION OF NUCLEIC ACIDS | GENENTECH, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3980544-A1 | TARGETED INTEGRATION OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | PTPN1 864/4885SLCO2B1 1640/4885KDM1A 1395/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | PTPN1 864/4885SLCO2B1 1640/4885KDM1A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.